Print

Senesco Technologies, Inc. (SNT) Announces Presentation on Combination Therapy With Novel Nanoparticle, SNS01-T, and Bortezomib Results in Synergistic Cytotoxicity In Vitro and In Vivo in Multiple Myeloma  
5/14/2013 10:59:42 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI), announced today that a poster presentation will be delivered at the 16th Annual Meeting of the American Society of Gene & Cell Therapy. The conference will be held May 15-18th, 2013 at the Salt Palace Convention Center in Salt Lake City, Utah. The Company will present during the Cancer-Targeted Gene & Cell Therapy: Viral Vector / siRNA-Mediated Therapies Session, which will begin Thursday, May 16, at 4:00 p.m. The poster presentation, entitled “Combination Therapy with Novel Nanoparticle, SNS01-T, and Bortezomib Results in Synergistic Cytotoxicity In Vitro and In Vivo in Multiple Myeloma”, will be delivered by Catherine Taylor, who is from Senesco CSO John Thompson’s research laboratory at the University of Waterloo in Ontario, Canada.

Help employers find you! Check out all the jobs and post your resume.

//-->